Kirin Brewery Co., Ltd. (KNBWY) And Astellas Pharma Inc. Enter Into Licensing Agreement On Immunosuppressive Fully Human Monoclonal Antibody  
1/24/2007 12:04:16 PM

Tokyo, Jan 24, 2007 (JCN Newswire) - Kirin Brewery Company, Limited and Astellas Pharma Inc. announced today that they have entered into a license and collaborative research and development agreement under which Kirin and Astellas will exclusively collaborate in developing and marketing a fully human anti-CD40 antagonistic monoclonal antibody ("CD40 antagonistic mAb") worldwide.